Bringing a new drug to market in Oklahoma

Tuesday, July 7, 2015

By Scott Meacham, president and CEO of i2E
For The Oklahoman

Discovering and bringing a new drug to market is not for the faint of heart.

But when the challenge is as big as fighting antibiotic-resistant bacteria, and the scientist is as intrepid as Dr. Anne Pereira, amazing results can prevail.

Pereira, the scientific founder of Biolytx Pharmaceuticals and Dean of the Graduate College and Associate Dean for Research in the College of Pharmacy at the University of Oklahoma Health Sciences Center (OUHSC), has been working nearly three decades on fighting gram-negative Pseudomonas.

These insidious bacteria, which are present all around us, generally don’t cause trouble for healthy people. Instead, they like to attack folks who are sick or weakened — burn victims, cancer patients, premature babies, or folks in intensive care, just to name a few.

Many of these bacteria have become antibiotic-resistant. Further, these clever and sneaky bugs remember the antibiotics they’ve resisted before, so new versions of old drugs lose their infection-fighting effectiveness fast.

Biolytx Pharmaceuticals has a novel new drug developed from a peptide (a small part of a protein) that is created by the human body. Bacteria haven’t seen these drugs before, which means that Biolytx’ drugs could wipe out certain infections that are antibiotic resistant today.

Biolytx is approaching what could be the final stretch of pre-clinical testing, leading to an Investigational New Drug (IND) application, which is the FDA’s precursor to Phase I and II clinical trials.

Read the rest of this story at

For other recent research news, take a look at this story, "Oklahoma scientist explores 'promising' therapies for pancreatic, liver cancers,"also on

For more information about Oklahoma's bioscience industry, look at the Chamber's website and that of i2e.